Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.
Saved in:
| Title: | Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. |
|---|---|
| Authors: | Krüger, Klaus1 (AUTHOR), Burmester, Gerd Rüdiger2 (AUTHOR), Wassenberg, Siegfried3 (AUTHOR), Thomas, Matthias H.4 (AUTHOR) matthias.thomas@msd.de |
| Source: | Rheumatology & Therapy. Jun2020, Vol. 7 Issue 2, p371-382. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21986576 |
|---|---|
| DOI: | 10.1007/s40744-020-00204-9 |
